Company research
ImageneBio, Inc.
CIK 1835579Updated Sep 26, 2026
SecurityIMA · NASDAQ · equity
Name history
Ikena Oncology, Inc. · through Jul 25, 2025
IMA price & chart
Loading TradingView…
NASDAQ:IMA on TradingView ↗About the company
Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company’s program, olevaprubart (formerly IMG-007), is a receptor targeting, nondepleting anti-OX40 monoclonal antibody with multiple differentiating features. Imagene has completed Phase 1b/2a clinical trials of olevaprubart in both atopic dermatitis and alopecia areata and is currently conducting a Phase 2b clinical trial of olevaprubart in patients with moderate-to-severe atopic dermatitis. For more information, please visit www.imagenebio.com.
In the news
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ↗
Seeking Alpha
ImageneBio, Inc. GAAP EPS of -$9.64 ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 152,976,000Source | 141,510,000Source | 192,092,000Source | 172,259,000Source |
| Property, Plant and Equipment, NetUSD | 0Source | 593,000Source | 2,335,000Source | 3,205,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 94,532,000Source | 39,393,000Source | 119,894,000Source | 59,919,000Source |
| Assets, CurrentUSD | 140,288,000Source | 127,169,000Source | 178,662,000Source | 160,010,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 4,939,000Source | 2,783,000Source | 3,197,000Source | 3,063,000Source |
| Operating Lease, Right-of-Use AssetUSD | 790,000Source | 3,635,000Source | 5,686,000Source | 5,255,000Source |
| Other Assets, NoncurrentUSD | 4,878,000Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 19,837,000Source | 15,576,000Source | 22,335,000Source | 25,290,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | — | 48,000Source | 48,000Source | 36,000Source |
| Additional Paid in CapitalUSD | 363,094,000Source | 457,437,000Source | 452,142,000Source | 361,915,000Source |
| Retained Earnings (Accumulated Deficit)USD | -230,053,000Source | -331,619,000Source | -282,385,000Source | -214,219,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 87,000Source | 68,000Source | -48,000Source | -763,000Source |
| Stockholders' Equity Attributable to ParentUSD | 133,139,000Source | 125,934,000Source | 169,757,000Source | 146,969,000Source |
| Liabilities and EquityUSD | 152,976,000Source | 141,510,000Source | 192,092,000Source | 172,259,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,234,000Source | 10,778,000Source | 14,205,000Source | 21,503,000Source |
| Operating Lease, Liability, CurrentUSD | 2,262,000Source | 3,784,000Source | 3,558,000Source | 1,907,000Source |
| Accounts Payable, CurrentUSD | 1,439,000Source | 897,000Source | 2,066,000Source | 2,093,000Source |
| Operating Lease, Liability, NoncurrentUSD | 713,000Source | 3,737,000Source | 7,180,000Source | 3,787,000Source |
| Other Liabilities, NoncurrentUSD | 870,000Source | — | — | — |
| Additional Financial Items | ||||
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 175,500,000Source | 156,900,000Source |
| Deferred Revenue, CurrentUSD | 0Source | — | — | — |
| Deferred Tax Liabilities, NetUSD | 0Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -45,349,000Source | -49,234,000Source | -68,166,000Source | -68,765,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 400,000Source | — | — | — |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 15,391,000Source | 5,295,000Source | 7,632,000Source | 7,525,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | -2,820,000Source | -1,169,000Source | -2,870,000Source | -291,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | — | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -47,844,000Source | -46,004,000Source | -79,743,000Source | -74,109,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -5,814,000Source | -34,903,000Source | 64,144,000Source | -99,284,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | 414,000Source | 1,431,000Source |
| Cash flows from financing activities: | ||||
| Payments for Repurchase of Common StockUSD | — | — | 663,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 135,468,000Source | — | 75,980,000Source | 1,095,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 82,414,000Source | — | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 94,532,000Source | 40,265,000Source | 121,172,000Source | 60,791,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 23,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 604,000Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 15,391,000Source | 5,295,000Source | 7,632,000Source | 7,525,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 175,500,000Source | 156,900,000Source |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | -12,000Source |
| DepreciationUSD | — | 490,000Source | 1,020,000Source | 751,000Source |
| Gain (Loss) on Sale of PropertiesUSD | — | — | -5,000Source | -173,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | 0Source | -99,000Source | — | — |
| General and Administrative ExpenseUSD | 20,726,000Source | 23,679,000Source | 24,925,000Source | 22,201,000Source |
| Income Tax Expense (Benefit)USD | -350,000Source | 152,000Source | -162,000Source | 0Source |
| Investment Income, InterestUSD | — | — | 7,111,000Source | 2,149,000Source |
| Net Income (Loss) Attributable to ParentUSD | -45,349,000Source | -49,234,000Source | -68,166,000Source | -68,765,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -52,395,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 2,752,000Source | 9,891,000Source | — | — |
| Operating ExpensesUSD | 49,251,000Source | 58,973,000Source | 84,577,000Source | 86,522,000Source |
| Operating Lease, ExpenseUSD | — | 2,051,000Source | 1,714,000Source | 1,283,000Source |
| Operating Lease, Impairment LossUSD | 0Source | — | 1,744,000Source | — |
| Other Nonoperating Income (Expense)USD | 717,000Source | 2,518,000Source | 7,089,000Source | 2,139,000Source |
| Proceeds from Issuance of Long-term DebtUSD | 15,000,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 45,000Source | — | 136,000Source | 1,095,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 800,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 800,000Source | — | 9,160,000Source | 15,618,000Source |
| Operating Income (Loss)USD | -48,451,000Source | -58,973,000Source | -75,417,000Source | -70,904,000Source |
| Other Nonoperating Income (Expense)USD | 717,000Source | 2,518,000Source | 7,089,000Source | 2,139,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -45,699,000Source | -49,082,000Source | -68,328,000Source | — |
| Income Tax Expense (Benefit)USD | -350,000Source | 152,000Source | -162,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -45,349,000Source | -49,234,000Source | -68,166,000Source | -68,765,000Source |
| Earnings Per Share, BasicUSD per share | -9.64Source | -1.02Source | -1.63Source | -1.9Source |
| Earnings Per Share, DilutedUSD per share | -9.64Source | -1.02Source | -1.63Source | -1.9Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 4,870,906Source | 48,258,111Source | 41,735,081Source | 36,188,420Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | 48,258,111Source | 41,735,081Source | 36,188,420Source |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | -350,000Source | 152,000Source | -169,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 399,000Source | — | — | — |
| General and Administrative ExpenseUSD | 20,726,000Source | 23,679,000Source | 24,925,000Source | 22,201,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -34,633,000Source | — | — | — |
| InterestExpenseOperatingUSD | 489,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | 2,035,000Source | — | — | — |
| Investment Income, InterestUSD | — | — | 7,111,000Source | 2,149,000Source |
| Investment Income, NetUSD | — | 7,373,000Source | — | — |
| Labor and Related ExpenseUSD | 5,182,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -52,395,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 2,752,000Source | 9,891,000Source | — | — |
| Operating ExpensesUSD | 49,251,000Source | 58,973,000Source | 84,577,000Source | 86,522,000Source |
| Operating Lease, ExpenseUSD | — | 2,051,000Source | 1,714,000Source | 1,283,000Source |
| Other General and Administrative ExpenseUSD | 4,188,000Source | — | — | — |
| Research and Development ExpenseUSD | 28,525,000Source | 30,875,000Source | 59,652,000Source | 64,321,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 800,000Source | — | — | — |
Filing attachments
d166048dex991.htm · 8-K · 2026-08-05
EX-99.1 2 d166048dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ImageneBio Reports Second Quarter 2026 Financial Results SAN DIEGO, Aug. 5, 2026 (GLOBE NEWSWIRE) - ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended June 30, 2026, and provided a company update. Company Highlights Olevaprubart, also known as IMG-007, the potential first-in-class therapeutic targeting the OX40 pathway, is a non-T cell-depleting, ADCC-silenced, anti…
Read attachment ↗d151394dex991.htm · 8-K · 2026-05-07
EX-99.1 2 d151394dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update SAN DIEGO, May 7, 2026 (GLOBE NEWSWIRE) - ImageneBio, Inc. (Nasdaq: IMA) (“Imagene” or the “Company”) today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights …
Read attachment ↗d143873dex41.htm · 8-K · 2026-04-13
EX-4.1 2 d143873dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, (III) THE COMPANY …
Read attachment ↗d143873dex42.htm · 8-K · 2026-04-13
EX-4.2 3 d143873dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April [•], 2026, is entered into by and among ImageneBio, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the res…
Read attachment ↗